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For many years, conventional oncologic treatments such as surgery, chemotherapy,
and radiotherapy (RT) have dominated the field of non-small-cell lung cancer (NSCLC).
The recent introduction of immunotherapy (IT) in clinical practice, especially strategies
targeting negative regulators of the immune system, so-called immune checkpoint
inhibitors, has led to a paradigm shift in lung cancer as in many other solid tumors.
Although antibodies against programmed death protein-1 (PD-1) and programmed death
ligand-1 (PD-L1) are currently on the forefront of the immuno-oncology field, the first
efforts to eradicate cancer by exploiting the host’s immune system date back to several
decades ago. Even then, researchers aimed to explore the addition of RT to IT strategies
in NSCLC patients, attributing its potential benefit to local control of target lesions through
direct and indirect DNA damage in cancer cells. However, recent pre-clinical and clinical
data have shown RT may also modify antitumor immune responses through induction
of immunogenic cell death and reprogramming of the tumor microenvironment. This
has led many to reexamine RT as a partner therapy to immuno-oncology treatments
and investigate their potential synergy in an exponentially growing number of clinical
trials. Herein, the authors review the rationale of combining IT and RT across all NSCLC
disease stages and summarize both historical and current clinical evidence surrounding
these combination strategies. Furthermore, an overview is provided of active clinical trials
exploring the IT-RT concept in different settings of NSCLC.
Keywords: non-small-cell lung cancer, immunotherapy, checkpoint inhibitor, stereotactic body radiation therapy,
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INTRODUCTION
Radiotherapy (RT) has earned its place as one of three main pillars in non-small cell lung cancer
(NSCLC) treatment, alongside surgery and systemic agents. Traditionally considered as a means
of achieving local tumor control through induction of irreversible deoxyribonucleic acid (DNA)
damage in irradiated tumor cells, RT is used in routine clinical practice across all NSCLC disease
stages, whether with curative or palliative intent (1). However, since as early as 1953, reports have
been published describing tumor regression outside the radiation fields (2). This so-called “abscopal
effect” has more recently been postulated to be the result of a RT-induced antitumor immune
response. With the advent of modern immunotherapy (IT), the potential for immune activation by
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RT has become even more relevant. Indeed, mounting pre-
clinical and clinical evidence suggests a potential synergy between
RT and IT, creating opportunities for combining these two
treatment strategies, in NSCLC as in many other tumor types. In
order to harness these synergistic effects however, it is important
to understand the underlying mechanisms in which key factors
such as the type of IT used, the irradiated volume, as well
as timing, dose and fractionation of RT play a crucial role.
Herein, we review the rationale for combining IT and RT
across different NSCLC disease stages and summarize the current
clinical evidence surrounding these novel treatment approaches.
Furthermore, an overview is provided of active clinical trials
exploring the IT-RT concept in different settings of NSCLC.
For this review, we conducted a search of PubMed, Embase
and Web of Science for original research, review articles
and meta-analyses relevant to the combination of RT and
IT in NSCLC from inception until March 2019, yielding a
total reference count of 708. After removal of duplicates,
394 abstracts were screened by one reviewer, of which 62
qualified for full text screening. In case of multiple publications
reporting on the same study population, manuscripts with
the longest follow-up were selected for inclusion. The cited
and citing references of the included studies were checked for
additional relevant publications. Finally, a total of 42 published
original research papers and abstracts were included and their
results will be discussed below. Furthermore, using the search
terms “radiotherapy,” “immunotherapy,” “immune,” “vaccine,”
and “checkpoint,” the international clinical study database
Clinicaltrials.gov was queried for currently active trials in the area
of NSCLC combining both treatment modalities.
IMMUNOLOGIC EFFECTS OF
RADIOTHERAPY
It has been over a decade since new insights into the complex
interplay between cancer and the host’s immune system, known
as the cancer immunoediting hypothesis (3), have revolutionized
our understanding and approach to this disease. Besides sparking
interest in the development of novel immunotherapeutic drugs
targeting different aspects of the so-called cancer-immunity
cycle (4), it also prompted researchers to reassess the role
of conventional oncological therapies—most notably RT—in
anticancer immunity.
In-situ Vaccination
The principal mechanism of action of ionizing radiation is
the induction of irreparable DNA damage in tumor cells—
either directly or indirectly through free radicals. Under the
right circumstances, radiation-damaged tumor cells may in
turn undergo a phenomenon called “immunogenic cell death,”
whereby an increased expression of calreticulin facilitates their
phagocytosis by dendritic cells (DCs) and promotes the secretion
of pro-inflammatory cytokines (Figure 1) (5). In addition,
radiation-induced DNA damage leads to the accumulation of
cytosolic DNA, which stimulates the production of type I
interferons (IFN-I) through cyclic guanosine monophosphate-
adenosine monophosphate synthase (cGAS)/stimulator of IFN
genes (STING) nucleic acid-sensing pathways (6–8). RT also
triggers the release of several other danger-associated molecular
patterns, including adenosine triphosphate and high mobility
group box 1, which together with IFN-I, prompt DC recruitment
and activation (5, 9). After subsequently migrating to the tumor-
draining lymph node, DCs will present tumor-associated antigen
(TAA) to cluster of differentiation 8 positive (CD8+) T-cells
so that cross-priming and activation of these cytotoxic T-
cells can occur (10, 11). T-cell trafficking back to the tumor
microenvironment is aided by radiation-induced chemokines
such as C-X-C chemokine ligand 16 (CXCL16) by the tumor
and intercellular (ICAM) and vascular cell adhesion molecules
expression by the endothelial cells (12, 13). There, cytotoxic
T lymphocytes will meet residual irradiated tumor cells that
show increased expression of major histocompatibility complex
class I (MHC-I), Fas and natural killer group 2, member D
ligands, thus rendering them more sensitive to cell killing (14–
16). In theory, these TAA-specific T-cells could also home to
cancerous lesions outside of the radiation field, thereby leading
to abscopal responses.
The Role of RT Dose
It has been stipulated that RT in conventional dose-fractionation
regimens [i.e., 1.8–2 Gray (Gy) per fraction] may elicit
profound immunosuppressive responses in tumors. Such effects
include recruitment of notoriously pro-tumorigenic myeloid-
derived suppressor cells (MDSCs) and M2 tumor-associated
macrophages (TAM), as well as a preferential increase of
the regulatory T-cell (Treg) population, either independently,
due to their intrinsic radioresistance or as a consequence
of RT-induced upregulation of transforming growth factor
beta (3, 17–20). Conversely, 2 Gy daily RT fractions may
also have the potential to boost antitumor immune responses
through in-situ vaccination, as demonstrated by the detection
of TAA-specific CD8+ T-cells in the circulation of colorectal
(21) and prostate cancer patients (22) receiving standard
(chemo)radiation. Nevertheless, in pre-clinical experiments
comparing immunologic effects of conventional RT doses to
those of hypofractionated regimens, more specifically if ≥6Gy
per fraction is being delivered, or even single high-dose radiation,
profound differences are observed (9). For example, Reits et al.
showed that the expression of MHC-I and associated tumor
peptides was higher with increasing RT doses (16). Other
reports demonstrate that higher doses may lead to greater
upregulation of other stimulatory immune signals such as Fas
and ICAM, as well as enhanced tumor-specific CD8+ T-cell
infiltration (23, 24).
Interestingly, the enhanced immunogenicity of increasing
radiation doses does not seem to extend beyond a certain dose
range (24). This could be explained in part by the induction
of DNA exonuclease Trex1 at doses larger than 18–20Gy
per fraction, which degrades cytosolic DNA, thus preventing
activation of the cGAS/STING pathway and thereby abrogating
a potential antitumor immune response (8).
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FIGURE 1 | Immunological effects or radiotherapy. Radiotherapy may induce immunogenic cancer cell death, characterized by increased expression of
danger-associated molecular patterns (DAMPs) and type I interferon (IFN-I), in turn causing the release of tumor-associated antigens (TAAs). Activated dendritic cells
(DCs) will present these TAAs to T-cells located in the tumor-draining lymph node, which also carry inhibitory receptors programmed death protein 1 (PD-1) and
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) on their cell surface. T-cell homing back to the tumor microenvironment is aided by radiation-induced
chemokines, as well as upregulation of intercellular (ICAM) and vascular cell adhesion molecules (VCAM) on endothelial cells. Increased expression of major
histocompatibility complex (MHC), Fas and natural killer group 2, member D (NKG2D) by residual irradiated tumor cells facilitates their destruction. CD, cluster of
differentiation; L, ligand; LFA1, lymphocyte function associated antigen 1; PD-L1, programmed death ligand-1; TCR, T-cell receptor; VLA1, integrin alpha 1.
The Role of RT Timing and Sequencing
Immunologic effects of RTmay not only be sensitive to variations
in dose and fractionation, they also appear to be time-dependent.
For instance, in vitro data demonstrate an increase in the
MHC-I-associated peptide pool after approximately 8 h and up
to 11 days or more following high doses of radiation (16).
Kinetics of RT-induced intratumoral immune cell activation
were also studied in vivo, particularly in cervical cancer patients
treated with conventionally fractionated RT and concurrent
chemotherapy (25). Repeated cervical brushings showed an
enrichment of activated DCs at the tumor site during the first
week of chemoradiation, potentially corresponding to treatment-
induced antigen presentation. Meanwhile, the proportion of
activated and proliferating T-cells experienced an initial decline
in week 1, but quickly recovered and even increased in weeks
3–5, supporting the in-situ vaccination hypothesis. Interestingly,
changes in the populations and/or activation status of myeloid
and T-cells appeared to be more pronounced at the tumor site
in comparison to peripheral blood samples. Findings such as
these provide important insights into immune dynamic changes
in the tumor microenvironment and could therefore further the
development of rational IT-RT combination strategies, especially
regarding optimal treatment sequencing.
The antitumor effects of antigen-specific immunotherapy
(ASI), for instance, rely on the generation of a potent cellular
immune response against a specific TAA. A prime example of
this is tecemotide, a peptide vaccine containing a liposomal
formulation of tumor-associated mucin 1 (MUC1), which is
designed to elicit a MUC1-specific T-cell proliferative response.
As the initial depletion of effector cell types from the tumor
microenvironment caused by repeated moderate doses of RT
could abrogate any previously induced immune infiltrate, ASI
such as tecemotide may prove most useful when administered
after RT, serving as a booster for the immune cells generated
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by in-situ vaccination. Moreover, the RT-induced expression of
chemotactic signals such as CXCL16may facilitate homing of any
TAA-specific T-cells to the irradiated lesion.
Similarly, RT may be used to prime tumors in order to render
them more susceptible to adoptive IT, such as lymphokine-
activated killer cell (LAK), DC, cytokine-induced killer cell
(CIK), tumor-infiltrating lymphocyte (TIL) and chimeric antigen
receptor (CAR) T-cell therapy. Important work by Klug et al.
demonstrated in murine as well as xenotransplanted and human
primary tumors that even single low doses of RT (≤2Gy) may
be capable of reprogramming the tumor microenvironment—
in particular polarizing TAMs to an M1 phenotype—causing
inducible nitric oxide synthase-mediated vascular normalization,
and thus facilitating tumor homing of transferred T-cells (26).
In addition, RT may enhance cytotoxicity of CIKs through
upregulation of signaling pathways required for their antitumor
activity, includingNK-cell receptor ligands and Fas. In turn, CIKs
are known to secrete proinflammatory cytokines such as tumor
necrosis factor alpha and interferon gamma (IFNÈ), thereby
enriching local immune responses (27). With regards to CAR T-
cell therapy, De Selm et al. demonstrated increased efficacy after
previous exposure of tumors to low-dose RT in their orthotopic
pancreatic cancer model (28).
Of all IT-RT combinations, treatment regimens integrating
RT and immune checkpoint blockade (ICB) have garnered
the most interest in recent years. Simply put, the rationale
of a potential synergy between both treatments is that
the inhibition of immune checkpoints, such as cytotoxic
T lymphocyte antigen 4 (CTLA-4), programmed cell death
protein 1 (PD-1) and programmed cell death 1 ligand 1
(PD-L1), liberates T-cells from immunosuppression, thereby
increasing the in-situ vaccination effect of RT. Additional
benefits of ICB in the context of RT include: depletion
of intratumoral Treg cells (anti-CTLA-4), counteracting RT-
induced T-cell exhaustion through upregulation of PD-L1 (anti-
PD-(L)1) and a reduction of MDSC populations in the tumor
microenvironment (anti-PD-(L)1) (29). RT can also lead to
upregulation of PD-L1 expression in tumors, which has been
shown to be mediated by IFNÈ and may be an important
mechanism of radioresistance (30). Altogether, these findings
suggest concurrent administration of ICB with RT would be
optimal in order to exploit their full synergistic potential.
Nevertheless, encouraging results have been achieved with
sequential treatment regimens as well, in particular with the
adjuvant use of checkpoint inhibitors to CRT. In these types
of treatment schedules, timing may play an even greater role,
as in the PACIFIC trial, where multivariate analysis suggested
that initiation of anti-PD-L1 treatment before 2 weeks after
completion of chemoradiation was correlated with better overall
survival (OS) in comparison to initiation after 14 days or more
(31). Nevertheless, further analysis showed that durvalumab
initiated after longer time intervals still provided clinical benefit
in terms of progression-free survival (PFS) and time to distant
metastasis (32).
Less is known about the underlyingmechanisms of interaction
between RT and non-specific immunomodulatory drugs, such
as levamisole, or so-called active immunotherapy (i.e., Bacillus
Calmette-Guérin, BCG), making it more difficult to theorize their
optimal sequencing.
The Role of RT Target Volume and Organs
at Risk
As illustrated above, lymphocytes play a crucial role in antitumor
immunity. Unfortunately, one of the major drawbacks of
conventional oncological treatments is their tendency to cause
systemic lymphopenia, which is increasingly being recognized
to profoundly influence outcome. Indeed, several reports
have shown radiation-induced lymphopenia (RIL) to be an
independent predictor for poor survival in solid tumors (33, 34).
More specifically in NSCLC, besides the obvious consideration
of whether or not a patient is amenable to receive concurrent
chemotherapy, the definition of RT target volumes seems to be
a determining factor in the incidence of RIL. First, the sheer
size of the radiation field has a direct impact on lymphocyte
nadirs, as was demonstrated in a retrospective study by Tang et al.
(35). This effect could be explained by taking into consideration
unintentional RT doses to sites of lymphopoiesis (bone marrow)
and lymphocyte storage (spleen, lymph nodes), as well as
the amount of circulating immune cells passing through the
radiation field (36, 37). The latter is of particular importance in
thoracic RT, where organs at risk (OARs) characterized by high
blood flow such as the heart and lungs reside, thus exposing
a large proportion of circulating lymphocytes to radiation (33).
Due to their intrinsic radiosensitivity to doses even below 1Gy
(38) large volumes irradiated to relatively low doses (i.e., the low-
dose bath), inherent even to modern photon RT techniques such
as intensity-modulated radiotherapy, may significantly impact
the incidence of RIL. In theory, more conformal (e.g., proton
therapy) and faster (e.g., higher dose rate) dose delivery could aid
in limiting this exposure.
In addition to the direct hit of lymphocytes by RT, pre-
clinical data suggest irradiation of the draining lymph nodes
may also attenuate adaptive immune responses through altered
intratumoral chemokine expression and CD8+ T-cell trafficking
as compared to RT to the primary tumor alone (39). This in turn
adversely affected treatment outcome when RT was combined
with ICB.
Adding to the list of OARs to consider, Price et al.
demonstrated irradiating major areas of skin may also have
detrimental effects on antitumor immune responses. Their
experiments showed RT mobilizes Langerhans cells, a DC subset
present in the epidermis, which may subsequently migrate to the
draining lymph node where they cause an accumulation of Treg
cells (40).
On the other end of the benefit-risk balance of IT-RT
strategies stands the possibility of increased toxicity of combined
treatment. RT-induced immune-cell infiltration and subsequent
inflammation-associated normal tissue responses underlying the
occurrence of radiation-induced lung injury (i.e., radiation
pneumonitis and fibrosis) warrant further inquiry into a potential
interaction with immunotherapy (41). Most notably, it has been
postulated that combining RT with ICB may pose a particular
risk, as these drugs alone are known to cause severe, even
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potentially life-threatening, pneumonitis in a small subset of
patients. Reports of high-grade lung toxicities with concurrent
RT and anti-PD-(L)1 caution the use of such treatment schedules
outside of clinical trials (42). Even so, higher rates of pneumonitis
may be expected in a non-trial-enrolled population, as is the
case with ICB monotherapy (43). Regardless of the setting, all
available measures should be taken to minimize the incidence of
RT-related pulmonary toxicity, such as careful patient and tumor




Approximately one in four new NSCLC cases are diagnosed
with locally-advanced (LA-NSCLC) disease (44). In this setting,
RT may be offered as an adjunct to surgery in operable
patients, be it in the preoperative setting or after incomplete
resection, but will most frequently be used as definitive treatment
combined with chemotherapy (concurrently of sequentially) in
stage IIIB or (unresectable) stage IIIA disease. When combined
with platinum-based doublet chemotherapy, RT doses ranging
between 60 and 66Gy in 2Gy daily fractions over 6–7 weeks
are advocated (1). Despite many historical efforts to optimize
treatment schedules, LA-NSCLC treated with concurrent chemo-
radiotherapy is characterized by a poor 2-year overall and
progression-free survival, typically <60 and 30% respectively,
with median OS ranging between 2 and 2.5 years, even
in the most recent randomized series (45, 46). Analyses of
failure patterns after CRT reveal a substantial contribution
of locoregional recurrence, but an even greater proportion
of about 50% of patients experiencing distant progression
(47). Thus, it seems neither RT’s qualities in terms of local
control, nor the systemic antitumor effects of chemotherapy
are sufficient to offer long-term disease control in all LA-
NSCLC patients. Therefore, this setting may represent an
exciting opportunity for the development of innovative strategies
integrating immunotherapeutic agents into combined modality
treatment. This is why it is not surprising that LA-NSCLCwas the
first clinical entity in lung cancer in which the concept of immune
modulation with RT was explored.
Available Clinical Evidence (Table 1)
The earliest clinical data on IT-RT combinations in NSCLC date
back to the 1970’s and 80’s, when immuno-oncology was still in its
infancy. At the time, experience in leveraging the immune system
in order to eradicate cancer cells was mostly limited to the use of
non-specific immunostimulants.
One in particular, BCG, had garnered substantial interest
due to its encouraging results in hematologic malignancies,
which soon inspired the development of several pre-clinical
experiments and clinical studies in various other cancer
types (58). Specifically in lung cancer, trials evaluating BCG
or its methanol extraction residue in combination with
(chemo)radiation in LA-NSCLC unfortunately failed to show
any benefit in terms of survival (59–62). An interesting finding
however, was that when administered during or after RT, these
drugs seemed to inhibit the development of distant metastasis
(59, 60), suggesting that their potential immunogenic effects may
be more pronounced in the context of minimal (residual) disease.
The same allegedly applied to levamisole, a drug used
as an anthelmintic before its immunotropic properties were
discovered in animal cancer models. Several trials investigated
levamisole in conjunction with (chemo)radiation, among which
a phase III study initiated by the Radiation Therapy Oncology
Group (RTOG), unfortunately showing no difference in OS and
PFS compared to placebo, in both resectable and unresectable
NSCLC (63–67).
Meanwhile in Japan, research efforts were aimed at combining
RT with other non-specific immunopotentiators, namely
Picibanil (or OK-432) and polysaccharide K (PSK or Krestin).
In their non-randomized trial, Ogawa et al. demonstrated an
increased survival associated with the use of OK-432 and/or
PSK in addition to chemo-radiotherapy, but did not report
significance (68).
A decade later, the first clinical data on experimental RT
regimens integrating interferons as radiosensitizers in LA-
NSCLC started to emerge. Two smaller studies showed that
combining natural alpha-interferon or human recombinant
IFNÈ with hyperfractionated RT (60Gy in 1.25–1.5Gy fractions,
twice-daily) resulted in a marked increase in severe treatment-
related toxicity (i.e., esophagitis, radiation pneumonitis, and
fibrosis) (69, 70). While initial phase I/II results of concurrent
recombinant beta-interferon and conventionally fractionated RT
(60Gy in 2Gy fractions) were more encouraging, a phase III
study initiated by the RTOG demonstrated greater rates of both
acute and late side effects and failed to confirm any improvement
in overall survival (71). Although interferons play a vital role
in in-situ vaccination, it seems increasing systemic exposure
during RT may overstimulate these pathways, thereby inducing
radiation damage where it is least needed. Whether this effect
could be mitigated if RT doses were delivered more precisely and
conformally is an interesting hypothesis but remains unproven.
A final member of the non-specific immunomodulatory drug
family, referred to as bovine dialyzable leukocyte extract, was
evaluated concomitantly with chemoradiation in a phase I study,
demonstrating its safety and ability to increase certain T-cell
subpopulations (72).
As described above, RT and vaccine therapy may also offer
the potential of synergistic effects. One of the most extensively
studied ASI in LA-NSCLC is tecemotide (or L-BLP25). As
maintenance treatment after chemoradiation for stage III disease,
the anti-MUC1 vaccine first demonstrated an acceptable safety
and tolerability profile (48). Subsequent phase II results were
promising, thus warranting initiation of one of the largest phase
III IT-RT studies to date (49). The START trial enrolled over
1,500 patients and randomly assigned them two to one, to
receive either tecemotide or placebo within 4–12 weeks after
completion of chemo-radiotherapy, with the primary aim to
improve OS (73). Though this primary endpoint was not met
overall, the investigators found that patients receiving tecemotide
after concurrent chemoradiation did show a significant increase
in OS of about 10 months (HR 0.78, p = 0.016), as opposed to
those who had received sequential chemo-radiotherapy (HR 1.12,


































TABLE 1 | Clinical studies evaluating immunotherapy-radiotherapy combinations in locally advanced non-small cell lung cancer (LA-NSCLC), with primary endpoint results published or presented during the last
decade (2009–2019)a.
References Phase NSCLC setting (accrual) Immunotherapy Radiotherapy Design Primary outcome
ANTIGEN-SPECIFIC IMMUNOTHERAPY
Ohyanagi et al. (48) I Stage III, unresectable,
CR/PR/SD after CRT (N = 6)
Tecemotide ≥50Gy, sequentially or
concurrently with CT
CRT > tecemotideb ≥1 AE in 83.3% of pts, all G1
Butts et al. (49) IIB Stage IIIB, CR/PR/SD after CRT
(N = 65)c
Tecemotide Dose NS, sequentially or
concurrently with CT
• CRT > BSC +
tecemotideb
• CRT > BSC
Median OS 30.6 vs. 13.3m (HR
0.548, 95% CI 0.301–0.999)c
Mitchell et al. (50) (START) III Stage III, unresectable,
CR/PR/SD after CRT (N = 1,239)
Tecemotide ≥50Gy, sequentially or
concurrently with CT
• CRT > tecemotideb
• CRT > placebo
Median OS 58.7 vs. 57.3m (HR 0.89;
p = 0.111)
Patel et al. (51) II Stage III, unresectable,
non-squamous (N = 33)
Tecemotide 66 Gy/33 fx, concurrently
with CT
CRT > CT > tecemotide +
bevacizumab
≥G3 toxicity in 11 pts, G3
hypertension (n = 6)
Brunsvig et al. (52) II Stage III, inoperable (N = 23) GV1001 +
GM-CSF
60 Gy/30 fx, concurrently
with CT
CRT > GV1001 + GM-CSF No treatment-related SAE
Pujol et al. (53) I/II Stage III, unresectable, MAGE
A3-positive (N = 12)c
MAGE-A3
immunotherapeutic
NS CT > RT > MAGE-A3 Treatment-related AE in 7/12 pts; all
<G3. Induced CD4+ and CD8+
T-cell response in 5/6 and 2/6 pts
resp.c
IMMUNE CHECKPOINT BLOCKADE
Antonia et al. (31) (PACIFIC) III Stage III, unresectable (N = 713) Durva 54–66Gy, concurrently with
CT
• CRT > durva
• CRT > placebo
Median OS NR vs. 28.7m (HR 0.68;
p = 0.0025); median PFS 17.2 vs.
5.6m (HR 0.51)
Durm et al. (54) II Stage III, unresectable,
CR/PR/SD after CRT (N=92)
Pembro 59–66.6Gy, concurrently
with CT
CRT > pembro Median TMDD 22.4m (95% CI
17.9-NR)
Lin et al. (55) (DETERRED) II Stage III, unresectable (N = 40) Atezo 60–66 Gy/30–33 fx,
concurrently with CT
• CRT > CT + atezo
• CRT + atezo > CT
+ atezo
≥G3 atezo-related toxicity in 6 pts;
G5 TE fistula (n = 1). G3 radiation
pneumonitis (n = 1)
Peters et al. (56, 57)
(NICOLAS)
IA/II Stage III, unresectable (N = 79) Nivo • 66 Gy/33 fx, concurrently
with CT
• 66 Gy/24 fx, sequentially
after CT
CRT + nivo > nivo No ≥G3 post-RT pneumonitis, 1-year
PFS 50%
AE, adverse event(s); atezo, atezolizumab; BSC, best supportive care; CI, confidence interval; CR, complete response; CRT, chemo-radiotherapy; CT, chemotherapy; durva, durvalumab; fx, fraction(s); G, grade; GM-CSF, granulocyte-
macrophage colony-stimulating factor; Gy, Gray; HR, hazard ratio; m, month(s); nivo, nivolumab; NR, not reached; NS, not specified; pembro, pembrolizumab; PD, progressive disease; PR, partial response; pts, patients; resp.,
respectively; RT, radiotherapy; SAE, serious adverse event(s); SD, stable disease; surg, surgery; TE, tracheoesophageal; TMDD, time to metastatic disease or death; +, concurrently with; >, followed by.
a Included studies published before 2009 are not represented, as the authors feel the quality of these reports may not correspond to the current standards of evidence and/or practice (e.g., due to the use of outdated RT techniques),
thus may confound interpretation of the table contents.
bAdministration of tecemotide was preceded by a single low dose of cyclophosphamide.
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p = 0.38). This was confirmed in the updated results published
a few years later by Mitchell et al., adding exploratory biomarker
analyses which demonstrated a potential positive predictive value
of high blood levels of soluble MUC1 (sMUC1) for tecemotide
therapy (50). Given that negative prognostic associations were
observed between high sMUC1 and OS in the placebo group,
researchers proposed that an abundance of sMUC1 in the
circulation may reflect increased MUC1 expression by tumors
and therefore indicate a target for tecemotide-induced T-cell
immunity. A subsequent phase III trial, narrowing its study
population to concurrent chemoradiation, attempted to confirm
the previously demonstrated OS benefit of adjuvant tecemotide
but was terminated prematurely due to the discontinuation of the
tecemotide program in NSCLC.
More recently, Patel et al. hypothesized that vascular
endothelial growth factor-inhibitor bevacizumab may provide
additional immunomodulatory benefits when combined with
tecemotide following definitive chemoradiation for LA-NSCLC
(51). Their phase I study met its safety endpoint, but the
authors did report grade 4 (1/70) and 5 (1/70) toxicity during
maintenance treatment.
A second peptide-based vaccine studied in LA-NSCLC, called
GV1001, is derived from the functional domain of human
telomerase reverse transcriptase. Overexpression of this enzyme
in cancer cells helps maintain the integrity of telomere sequences,
thereby allowing them to avoid senescence. In their phase II
trial of maintenance vaccination following radiotherapy and
docetaxel for stage III NSCLC, Brunsvig et al. demonstrated a
trend toward improved PFS in patients exhibiting a GV1001-
specific T-cell response (52). The benefits of GV1001 in the
context of radiation may not be limited to immune activation,
as they may also include antifibrotic effects (74).
The cancer/testis antigen, MAGE-A3, has also been proposed
as a target for ASI in NSCLC and was investigated in one phase
I trial (53). One of four cohorts (n = 12) integrated RT into
protocol treatment, adding the MAGE-A3 immunotherapeutic
after sequential chemoradiation in unresectable stage III NSCLC.
In addition to demonstrating an acceptable toxicity profile,
a higher prevalence and magnitude of MAGE-A3-specific T-
cell responses were observed following chemoradiation in
comparison to other study arms not incorporating RT, suggesting
irradiated tumor tissue may present an ideal substrate for this
particular vaccine.
Several reports, originating primarily from Asian countries,
have described therapeutic efficacy of combining chemoradiation
with adoptive immunotherapy. A meta-analysis by Qian et al.
concluded that the addition of immune cell reinfusion (i.e., DC-
CIK, CIK, LAK, or TIL) to conventional NSCLC treatments
significantly improved 2-year OS (OR 2.45, 1.60–3.75; p < 0.001)
(75). Even more recently, a second meta-analysis focusing on
CIK treatment in lung cancer demonstrated increased objective
response and disease control rates, with 1- and 2-year OS in
favor of combined IT-RT treatment in the NSCLC subgroup
analyses (76).
Whereas, the previously discussed immunotherapeutics are
either no longer under investigation in conjunction with RT for
LA-NSCLC, or still in experimental stages of development, a true
paradigm shift in the treatment of LA-NSCLC was brought about
by the introduction of ICB. In this context, most studies to date
have investigated RT in conjunction with monoclonal antibodies
targeting the PD(L)-1 receptor interaction. First, consolidation
pembrolizumab (anti-PD-1) after chemoradiation in patients
with unresectable stage III NSCLC demonstrated increased 2-
year PFS (44.6%) and time tometastatic disease or death (TMDD;
median 22.4 months) compared to historical controls (54), but
the most convincing results to date were achieved with PD-
L1 inhibition. The PACIFIC study, a randomized phase III
trial evaluating durvalumab or placebo after concurrent chemo-
radiotherapy for unresectable stage III disease, initially achieved
very convincing results in terms of PFS (HR 0.52) and TMDD
(median 23.2 months, HR 0.52) (77). More recently, the trial
also showed practice-changing evidence through a significantly
prolonged OS of maintenance durvalumab as compared with
placebo (HR 0.68, p = 0.0025) across all prespecified subgroups
(31). This subsequently led to its FDA and EMA approval as
standard treatment for tumors with a PD-L1 expression of ≥1%
in the majority of jurisdictions. In addition, although there
is currently no formal evidence on the effect of durvalumab
following sequential chemo-radiotherapy in LA-NSCLC, some
countries have already granted approval for this setting as well.
Nevertheless, further research is ongoing to define the impact of
durvalumab after sequential chemoradiation, as it is recognized
that results may not simply be transferable due to aspects
inherent to the treatment approach as such and/or because of a
difference in patient population, as clearly demonstrated by the
START trial. Moreover, since detailed data of the RT delivered
in the PACIFIC study, such as dose-volume parameters, are
lacking, more thorough RT quality assurance will be of utmost
importance in future clinical trials.
The proof of durvalumab’s manageable safety profile
as a sequential treatment after chemoradiation, in line
with previous studies of ICB monotherapy, encouraged
researchers to attempt combining all three treatment modalities
concurrently. In the DETERRED trial, 40 LA-NSCLC patients
were randomized 3:1 to receive standard chemo-radiotherapy
with or without concomitant atezolizumab (anti-PD-L1)
followed by atezolizumab maintenance treatment (55). No
increased toxicity was found when comparing both regimens.
Similarly, the recently published interim safety analysis of the
ETOP NICOLAS study (n = 21) established that the addition of
nivolumab (anti-PD-1) concurrently to chemoradiation followed
by nivolumab maintenance, did not lead to the occurrence of
grade ≥3 pneumonitis by 3 months post-RT (56). Regrettably,
phase II results of this trial presented at the 2019 European
Society of Medical Oncology congress showed it did not meet its
primary efficacy endpoint with a 1-year PFS of 50% (57). Further
evidence from other ongoing trials (Table 3) are eagerly awaited.
Metastatic NSCLC
About half of all lung cancer patients are diagnosed with
advanced disease (44). Though the therapeutic landscape of
metastatic NSCLC (M-NSCLC) has changed tremendously over
the past decade, 5-year relative survival remains low at around
6%. Traditionally, RT is offered as a palliative treatment
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option for these patients (78). In recent years, however, there
is growing evidence that RT could also be offered as a
local—potentially curative—treatment in a subset of M-NSCLC
patients who present with a limited number of metastases,
termed oligometastatic disease (79). In this context, stereotactic
body radiotherapy (SBRT), using high doses per fraction
and precise dose delivery, is often proposed to ablate visible
lesions, built upon the finding that further disease progression
most often originates from these known disease sites (80).
Recent randomized controlled trials (RCTs) have confirmed this
hypothesis, the ablative approach yielding OS and PFS benefit
(81–83). Nevertheless, this evidence was gathered at a time
when IT had not yet made its way into standard first- and/or
second-line treatment for M-NSCLC. Considering the potential
immunogenicity of RT, perhaps its benefits could extend beyond
the oligometastatic setting, boosting immunotherapeutic efficacy
through in-situ vaccination and the induction of abscopal
responses, while debulking sites of gross disease in polymetastatic
patients. IT, in turn, may reduce tumor loads or slow down the
process of metastatic spread, creating a window of opportunity
for local ablative treatments, such as SBRT.
Available Clinical Evidence (Table 2)
As in LA-NSCLC, research efforts into IT-RT combinations for
the treatment of M-NSCLC date back to a time when ICB had not
yet been developed. Studies with limited patient numbers have
explored the potential benefit of different IT-RT combinations.
Among the first experiments with RT and immunocytokine
therapy in lung cancer demonstrated an acceptable safety
profile and potential immunogenicity of Selectikine or NHS-
IL2 (genetically modified interleukin-2 fused with DNA-targeting
antibody NHS76), administered after local irradiation of a single
pulmonary lesion in 13 M-NSCLC patients (84). Interestingly,
both long-term survivors developed thyroiditis during treatment,
which was only seen in one other patient, indicating that the
incidence of immune-related adverse events may be linked to
intrinsic IT susceptibility.
Recognizing the importance of DCs in RT-induced immune
activation, Golden et al. attempted to stimulate DC maturation
by combining radiation with granulocyte-macrophage colony-
stimulating factor (GM-CSF), ultimately aiming to elicit abscopal
responses (85). Almost half of the 41 patients studied had M-
NSCLC (n = 18), four of whom demonstrated a partial (2/4) or
complete (2/4) response in non-irradiated lesions. In addition,
patients experiencing an abscopal response (11 in total) showed
significantly better OS (HR 2.06).
Similar to GM-CSF, the feline McDonough sarcoma-
like tyrosine kinase 3 ligand CDX-301 has the ability to
induce differentiation of bone marrow precursor cells into
distinct subsets of DCs. Preliminary results from an ongoing
trial investigating SBRT to an intrathoracic disease site and
concurrent CDX-301 in M-NSCLC are promising, with more
than half of patients (5/9) achieving partial remission (86). Of
note, all five responders had been previously treated with ICB.
Though disappointing phase III results, such as those of
the START trial in LA-NSCLC (50, 73) and the STOP trial
investigating maintenance belagenpumatucel-L in M-NSCLC
(98), might have negatively impacted general enthusiasm for
antigen-specific immunotherapeutic approaches in NSCLC,
novel mRNA-based vaccines may be more promising. Targeting
five and six different TAAs respectively, CV9201 and its successor
CV9202 have shown an acceptable safety profile and evidence
of immune activation when delivered after or concurrently with
local fractionated RT for stage IIIB-IV disease (87, 99). Additional
research is required to determine whether this combination
treatment can improve long-term outcome.
The largest body of available IT-RT evidence in M-NSCLC
describes the marriage of radiation and ICB. While Formenti
et al. performed a pioneering study on abscopal effects
with ipilimumab (88), research subsequently published focused
mainly on combining RT with anti-PD-1 antibodies, due to their
proven efficacy as monotherapy in M-NSCLC.
Early results of two phase I trials, comparing different—
radical or palliative—RT dose-fractionation schedules given
concurrently with escalating doses of pembrolizumab,
demonstrated acceptable toxicity of combined treatment
and encouraging disease control rates (DCR) of up to 68%
(89, 90). Moreover, Kumar et al. observed a trend for improved
PFS with higher RT doses, supporting the notion that these
could potentially be more immunogenic (90). Another cleverly
designed study attempted to elucidate the role of radiation as
a salvage treatment for M-NSCLC refractory to ICB, adding
SBRT onto pembrolizumab treatment only at the time of disease
progression (100). Stable disease and systemic responses were
achieved in 10 and 2 of the 21 patients who completed study
treatment, respectively.
Early safety data on the concurrent use of other anti-PD-
1 drugs (e.g., cemiplimab) with RT appear to be reassuring
(92), although caution is advised when treating brain metastases
radiosurgically in conjunction with nivolumab, especially in the
presence of significant peritumoral edema (93).
Sequential approaches were also evaluated, initially for
nivolumab (94), but more recent phase I and II trials focused
on pembrolizumab after local ablative treatment for M-NSCLC.
For instance, Theelen et al. performed a RCT of pembrolizumab
either without or after SBRT (3 × 8Gy) of a single NSCLC
metastasis (95). While the study’s primary endpoint criteria
were not met, a significant improvement of DCR was observed
in the experimental arm (64 vs. 40%; p = 0.04). Moreover,
subgroup analyses showed patients benefiting most from SBRT
were those with PD-L1 negative tumors at baseline. This finding
is particularly intriguing, since this is a population for which
single-agent PD-(L)1 inhibition is known to be of limited
benefit. Perhaps, pembrolizumab following SBRT may represent
a less toxic alternative to chemoimmunotherapy when aiming to
enhance response rates in M-NSCLC patients with a low PD-L1
tumor proportion score.
Despite promising results, some authors have advocated
abandoning the single-site abscopal approach and instead
propose to irradiate as much of the tumor burden as can
be safely achieved (101). They hypothesize that targeting only
one lesion may fail to account for tumor heterogeneity and
immunosuppressive features of bulky disease, thereby limiting
the probability of RT-induced systemic antitumor immune


































TABLE 2 | Clinical studies evaluating immunotherapy-radiotherapy combinations in metastatic non-small cell lung cancer (M-NSCLC), with primary endpoint results published or presented during the last decade
(2009–2019).
References Phase NSCLC setting (accrual) Immunotherapy Radiotherapy Design Primary outcome
NON-SPECIFIC IMMUNOTHERAPY
van den Heuvel et al. (84) IB Stage IV, CR/PR/SD after 1st line
CT (N=13)
NHS-IL2 20 Gy/5 fx, single
pulmonary nodule
RT > NHS-IL2 ≥G3 treatment-related toxicity in 3
pts
Golden et al. (85) NS Stage IV, ≥3 sites of measurable
disease, SD/PD on CT (N = 18)a
GM-CSF 35 Gy/10 fx, 2 lesions
consecutively
CT + RT lesion 1 +
GM-CSF > CT + RT lesion
2 + GM-CSF
Abscopal response in 4/18 pts
Ohri et al. (86) II Stage IV, ≥2 measurable disease
sites (N = 9)
CDX-301 30–54 Gy/1–5 fx, single
intrathoracic site of disease
SBRT + CDX-301 5/9 pts with PFS at 4 m
ANTIGEN-SPECIFIC IMMUNOTHERAPY
Papachristofilou et al. (87) IB Stage IV, PR/SD after 1st line CT
or TKI, ≥2 sites of disease (N =
26)
CV9202 20 Gy/4 fx, single lesion • RT + CT + CV9202
• RT + CV9202
• RT + TKI + CV9202
≥G3 treatment-related AE in 4/26 pts
IMMUNE CHECKPOINT BLOCKADE
Formenti et al. (88) I/II Stage IV, ≥2 measurable
metastatic sites (N = 39)
Ipi • 30 Gy/5 fx
• 27 Gy/3 fx
Single lesion
RT + ipi CR, PR and SD in 2, 5 and 5/21
evaluable pts resp.
Tang et al. (89) I Stage IV, ≥2 sites of disease (N
= 21)
Pembro • 50 Gy/4 fx, single liver or
lung lesion
• 45 Gy/15 fx, SIB allowed
up to 60Gy larger field
RT + pembro G2 and G3 treatment-related AE in 8
and 3/21 pts resp.
Kumar et al. (90) (PEAR) I Stage IV, requiring palliative
thoracic RT (N = 14)
Pembro • 20 Gy/5 fx
• 36 Gy/12 fx
RT + pembro No DLT
Decker et al. (91) I/II Stage IV, ≥2 measurable disease
sites (N = 8)
Pembro 30 Gy/3–5 fx, single site of
disease
Pembro until irPD > SBRT
+ pembro
No ≥G2 treatment-related AE during
and post-SBRT
Moreno et al. (92) I Stage IV, PD after ≥1st line
treatment, requiring palliative RT
(N = 53)
Cemi 27 Gy/3 fx • RT + cemi
• Cemi
G5 treatment-related pneumonitis (n
= 1). ORR 18.2 vs. 40.0%; DCR 72.7
vs. 60/0%
Alameddine et al. (93) I Stage IV, ≤10 cc untreated brain
metastases (N = 7)a
Nivo 15–20 Gy/1 fx, brain
metastasis
SRS + nivo Treatment-related AE in 3/5 evaluable
pts
Miyamoto et al. (94) NS Stage IV, ≥1 lesion amenable to
SBRT outside brain/bone (N = 6)
Nivo 25.5–48 Gy/3–4 fx, single
lesion
SBRT > nivo G3 pneumonitis in 1/6 pts
Theelen et al. (95)
(PEMBRO-RT)
II Stage IV, ≥2 separate lesions,
after ≥1st line treatment (N = 76)
Pembro 24 Gy/3 fx, single tumor site • SBRT > pembro
• Pembro
ORR at 12w 36 vs. 18% (p = 0.07)
Luke et al. (96) I Stage IV, ≥2 metastases, after
≥1st line treatment (N = 7)a
Pembro 30–50 Gy/3–5 fx, 2–4
metastases, partial for
metastases >65mL
SBRT > pembro ≥G3 treatment-related toxicity in 6/73
pts
Bauml et al. (97) II Stage IV, ≤4 metastases (N =
45)
Pembro Stereotactic or standard
fraction, dose NS
LAT > pembro PFS after LAT 19.1m vs. historical
6.6m (p = 0.005)
AE, adverse event(s); atezo, atezolizumab; cc, cubic centimeter; cemi, cemiplimab; CR, complete response; CT, chemotherapy; DCR, disease control rate; fx, fraction(s); G, grade; GM-CSF, granulocyte-macrophage colony-stimulating
factor; Gy, Gray; m, month(s); mL, milliliter; ipi, ipilimumab; ir, according to immune-related response evaluation criteria in solid tumors; LAT, local ablative treatment (i.e. surgery, chemotherapy, radiotherapy, radiofrequency ablation or a
combination of the above); nivo, nivolumab; NR, not reached; NS, not specified; ORR, objective response rate; pembro, pembrolizumab; PD, progressive disease; PR, partial response; pts, patients; resp., respectively; RT, radiotherapy;
SAE, serious adverse event(s); SD, stable disease; surg, surgery; TE, tracheoesophageal; TKI, tyrosine kinase inhibitor; TMDD, time to metastatic disease or death; +, concurrently with; >, followed by.

















































































TABLE 3 | Currently ongoing trials (i.e. not yet recruiting, recruiting and enrolling by invitation) evaluating immunotherapy-radiotherapy combinations in non-small cell lung cancera.
Study identifier
(acronym)
Phase NSCLC setting (accrual) Immunotherapy Radiotherapy Design Outcome Institution/group
NCT02599454 I Stage I, inoperable (N = 33) Atezo 50 Gy/4–5 fx SBRT + atezo MTD (DFS, ORR) University of California, Davis
NCT03148327
(ISABR)
I/II Stage I/IIA, inoperable (N =
105)
Durva • 50 Gy/4 fx
• 54 Gy/3 fx
• 65 Gy/10 fx
• SBRT + durva
• SBRT




II Stage I-IIA, not suitable for
surg (N = 216)
Durva 3–4 fx, dose NS • SBRT > durva
• SBRT
PFS (OS, LC, QoL) Vastra Gotaland Region
NCT03833154
(PACIFIC-4)
III Stage I-II lymph node
negative, planned for SBRT
(N = 630)
Durva NS • SBRT > durva
• SBRT > placebo
PFS (OS, QoL, tox, IM) AstraZeneca




Nivo • 50 Gy/4 fx
• 70 Gy/10 fx
• SABR + nivo
• SABR
EFS (OS, tox) M.D. Anderson Cancer Center
NCT03574220 I Stage IA-IIB, inoperable (N
= 15)
Pembro • 50 Gy/5 fx
• 60 Gy/3 fx




Ib/II Stage I-IIA, not suitable for
surg (N = 31)
Nivo • 54 Gy/3 fx
• 55 Gy/5 fx
SBRT > nivo Tox (DFS, OS, QoL, IM) Royal Marsden NHS Foundation
Trust
NCT03546829 I Early-stage, planned for
SBRT (N = 40)
Vancomycin NS • SBRT > vancomycin
• Vancomycin > SBRT
IM Abramson Cancer Center of the
University of Pennsylvania
NCT01720836 I/II Stage IA-IIIB (N = 30) Hiltonol (MUC1 +
poly-ICLC)




II Stage I-IIIA (N = 40) Pembro 12 Gy/1 fx, 50% of primary
tumor
• Pembro > SBRT > surg
• Pembro > surg




I Stage II-III, unresectable or
inoperable (N = 24)
Durva • 60 Gy/15 fx
• 60 Gy/30 fx
• Accelerated RT + durva
• Conventional RT + durva
Tox (feas, PFS, IM) NRG Oncology
NCT02621398 I Stage II inoperable or stage
III (N = 30)
Pembro 3D-RT or IMRT, 30 fx, dose
NS
CRT + pembro MTD, DLT (ORR, LC, DMFS
OS, PFS)
Rutgers Cancer Institute of New
Jersey
NCT04013542 I Stage II unresectable or
stage III (N = 20)
• Nivo
• Ipi
6–7w, dose NS RT + nivo + ipi > nivo Tox (PFS, OS, LC, ORR,
DOR)
M.D. Anderson Cancer Center
NCT03523702
(SPRINT)
II Stage II unresectable or
stage III (N = 63)
Pembro 4–7w, dose NS • PD-L1 <50%: CT + RT
• PD-L1 ≥50%: Pembro
+ RT




II Stage III, resectable (N =
55)
Durva 54Gy, number of fx NS CT + durva > surg > RT >
durva
Nodal response (pathologic
and radiologic ORR, EFS,
OS, tox)
Alliance Foundation Trials, LLC




45 Gy/25 fx • RT + durva > surg
• RT + durva + treme
> surg
Tox, feas (pathologic and
radiologic ORR, DOR, OS)
Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins
NCT03871153 II Stage III, resectable (N2) (N
= 25)
Durva 45–61.2 Gy/25–34 fx CT + durva > RT + durva
> surg > durva
Pathologic CR (nodal
response, tox, PFS)




















































































TABLE 3 | Continued
Study identifier
(acronym)
Phase NSCLC setting (accrual) Immunotherapy Radiotherapy Design Outcome Institution/group
NCT03631784
(KEYNOTE-799)
II Stage III, unresectable, 1st
line (N = 216)
Pembro 60 Gy/30 fx CRT + pembro > pembro Tox, ORR (PFS, OS) Merck Sharp & Dohme Corp.




60 Gy/30 fx CRT + ipi > nivo Tox, PFS (DMFS, ORR) H. Lee Moffitt Cancer Center and
Research Institute





59.4–66.6Gy, number of fx
NS
• CRT > nivo
• CRT > nivo + ipi
PFS (OS, DMFS, tox) Big Ten Cancer Research
Consortium
NCT03589547 II Stage III, PR/SD with CRT
(N = 25)
Durva 20 Gy/2–3 fx, primary tumor
only
SBRT + durva Tox, PFS (OS, LC, DMFS) Brown University
NCT03102242 II Stage IIIA/B, unresectable
(N = 63)
Atezo 60 Gy/30 fx Atezo > CRT DCR Alliance Foundation Trials
NCT03644823
(COM-IT-1)
II Stage III-IV, palliative treated
(N = 30)
Atezo 18 Gy/3 fx RT + atezo Tox (PFS) Oslo University Hospital
NCT03774732
(NIRVANA- Lung)




• 3D-RT: 18 Gy/3 fx
• RT + ICB
• ICB
OS (ORR, PFS, LC, QoL,
tox)
UNICANCER
NCT02839265 II Stage III-IV, ≥2 measurable
disease sites (N = 29)
CDX-301 30-54 Gy/1–5 fx, single
intrathoracic site of disease




II Stage IV, oligometastatic
(≤3 lesions) (N = 47)
Durva • SBRT: up to 10 fx, dose
NS
• Definitive RT: 60–66Gy,
fx NS
SBRT + CT + durva > surg
or definitive RT + durva




NCT03275597 Ib Stage IV, oligometastatic
(≤6 lesions) (N = 21)
• Durva
• Treme
30–50 Gy/5 fx, all sites of
disease
SBRT > durva + treme Tox (PFS, OS, IM) University of Wisconsin, Madison
NCT03509584 I Stage IV (N = 24) • Nivo
• Ipi
24 Gy/3 fx, single bone or
extracranial metastasis
• RT + nivo
• RT + nivo + ipi




I Stage IV (N = 80) • Nivo
• Ipi
3–5 fx, dose NS, 2–4 sites SBRT > nivo + ipi Tox (ORR, LC, IM) University of Chicago
NCT03168464 I/II Stage IV, ≥2 measurable
metastatic sites (N = 45)
• Nivo
• Ipi
30 Gy/5 fx, single lesion RT + ipi > nivo + ipi ORR (PFS, DOR, OS, IM) Weill Medical College of Cornell
University
NCT02444741 I/II Stage IV, ≥2 disease sites
(N = 104)
Pembro • 4 fx: SBRT
• 15 fx: IMRT, 3D-RT
or PBRT
• Pembro + RT
• Pembro > RT upon PD
Tox, ORR (PFS, OS) M.D. Anderson Cancer Center





• 24–45 Gy/3 fx
• 30–50 Gy/5 fx
Single lesion
RT + ICB ORR (PFS, OS, tox, QoL) West Virginia University
NCT03825510 NS Stage IV, ≥2 lesions




3–5 fx, dose NS, ≤3 sites SBRT > ICB OS, tox (PFS, LC) Crozer-Keystone Health System
NCT03867175 III Stage IV, ≤8 disease sites
(N = 116)
Pembro 3–10 fx, dose NS • SBRT > Pembro
• Pembro




















































































TABLE 3 | Continued
Study identifier
(acronym)
Phase NSCLC setting (accrual) Immunotherapy Radiotherapy Design Outcome Institution/group
NCT03391869
(LONESTAR)
III Stage IV (N = 270) • Nivo
• Ipi
NS Nivo + ipi > LCT > nivo +
ipi
OS (PFS, tox, QoL) M.D. Anderson Cancer Center
NCT03705403
(IMMUNOSABR2)
II Stage IV (N = 130) Darleukin (L19–IL2) 24 Gy/3 fx • SOC + Darleukin
• SOC
PFS (OS, QoL, IM) Maastricht University
NCT03158883 I Stage IV, ≥2 measurable
disease sites,
non-responsive or refractory
to ICB (N = 26)
Ave 50 Gy/5 fx SBRT + ave ORR (OS, PFS, DCR, DOR) University of California, Davis
NCT03224871 I Stage IV, ≥2 disease sites,
non-responsive or refractory




24 Gy/3 fx, single lesion RT + ICB > ICB + IL-2 DLT (DFS) University of California, Davis





• 24 Gy/3 fx
• 30 Gy/10 fx
• 20 Gy/5 fx
• 20–24 Gy/1 fx
Single lesion
RT + ICB PFS (LC, tox) Maastricht University
NCT03176173 II Stage IV, ≥1 extracranial





≤10 fx, dose NS • RT + ICB
• ICB
PFS (tox, OS, IM) Stanford University
NCT03044626
(FORCE)
II Stage IV, non-squamous,
2nd or 3rd line (N = 130)
Nivo 20 Gy/5 fx, single
metastatic site
• RT + nivo
• Nivo
ORR (PFS, OS, tox, QoL) AIO-Studien-gGmbH
NCT03489616
(CRAGMOLC)
NS Stage IV, oligometastatic
(2–5 metastases), PR/SD
after first-line CT (N = 45)
rhGM-CSF BED >45Gy, >4Gy per fx • CT + RT + rhGM-CSF
• CT
PFS (OS) Shandong Cancer Hospital and
Institute
3D-RT, 3-dimensional conformal radiotherapy; atezo, atezolizumab; ave, avelumab; BED, biologically effective dose; CR, complete response; CRT, chemo-radiotherapy; CT, chemotherapy; DCR, disease control rate; DFS, disease-
free survival; DLT, dose-limiting toxicity; DMFS, distant metastasis-free survival; DOR, duration of response; durva, durvalumab; EFS, event-free survival; feas, feasibility; fx, fraction(s); Gy, Gray; ICB, immune checkpoint blockade; IL,
interleukin; IM, immunomonitoring; IMRT, intensity-modulated radiotherapy; ipi, ipilimumab; MTD, maximum tolerated dose; nivo, nivolumab; LC, local control; LCT, local consolidation treatment; NS, not specified; NSCLC, non-small
cell lung cancer; OS, overall survival; ORR, overall response rate; PBRT, proton beam radiotherapy; PD, progressive disease; pembro, pembrolizumab; PFS, progression-free survival; PR, partial response; QoL, quality of life; rhGM-CSF,
human recombinant granulocyte-macrophage colony-stimulating factor; RT, radiotherapy; SABR, stereotactic ablative radiation therapy; SBRT, stereotactic body radiation therapy; SD, stable disease; SOC, standard of care; tox, toxicity;
treme, tremelimumab; w, week(s); +, concurrently with; >, followed by.
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activation. Luke et al. applied this logic in their phase I study,
allowing multisite SBRT of 2–4 metastases up to 1 week before
starting pembrolizumab in patients with advanced solid tumors
(96). Translating this concept into the oligometastatic NSCLC
setting, Bauml et al. initiated a phase II trial offering adjuvant
pembrolizumab to patients with a limited tumor burden (≤4
metastases) after eradication of all known sites of disease (97).
Median PFS exceeded that of historical controls, but whether
this benefit could be explained by a potential IT-RT synergy
remains unclear, as subgroup analyses comparing irradiated
to radiation-naive patients could not be performed. Questions
like these should be answered in RCTs, preferably stratifying
patients according to tumor burden, such as the ongoing
IMMUNOSABR2 study. Other ongoing IT-RT trials in M-
NSCLC are shown in Table 3.
Early-Stage NSCLC
Early-stage NSCLC (ES-NSCLC) represents about 15–20% of
all new lung cancer diagnoses (44). According to the latest
consensus guidelines, surgery remains the treatment of choice
for operable ES-NSCLC patients. For those unfit for or unwilling
to undergo surgical resection, SBRT is now the gold standard,
with an excellent safety profile and local control rates of
approximately 90% at 5 years (1). Unfortunately, as in LA-
NSCLC, the issue remains distant relapse, occurring in up to
20% or more (102–104). This number rises to over 30% in
most reports when regional recurrences are taken into account.
Certain clinical and molecular features associated with poor
prognosis have been identified (105, 106), justifying possible
treatment intensification in a subset of ES-NSCLC patients. In
this context, systemic treatment options could be considered
in order to eradicate micrometastatic disease and, in doing so,
improve long-term outcome. However, as factors determining
patients’ operability often coincide with those affecting their
eligibility for chemotherapy, a unique opportunity presents itself
for treatments with a relatively modest toxicity profile, such as IT.
Moreover, IT may offer additional benefits in terms of potential
synergistic effects with SBRT as detailed above. This rationale is
further supported by immunemechanistic studies demonstrating
hypofractionated RT for stage I NSCLC may stimulate immune
activation (107). As of yet, clinical data of combined IT-RT
approaches in ES-NSCLC are lacking, but trials investigating
their safety and efficacy are well underway (Table 3).
CONCLUSION
As of yet, the lion’s share of evidence demonstrating clinical
benefit with combined immunotherapy-radiotherapy strategies
for NSCLC is situated in locally-advanced disease. Even so,
a growing body of pre-clinical and clinical data has allowed
further insights into their synergy, providing a strong rationale
for extending this potential to other disease entities, such as
metastatic NSCLC. In addition, the excellent tolerability profile
of many novel immunotherapeutic drugs, both as monotherapy
and in conjunction with radiotherapy, as well as technological
and technical radiotherapy advances have created a window
of opportunity for the development of combined strategies in
earlier disease stages. Nevertheless, the success of future trials
will require well-reasoned hypotheses for radiotherapy timing,
dose and fractionation, in addition to selection of the appropriate
partner immunotherapy.
AUTHOR CONTRIBUTIONS
MSperformed the literature review and search of ongoing clinical
trials, on which both authors structured and synthesized the
evidence for the manuscript. YL critically revised all the drafts
and approved the final version for submission.
FUNDING
This work was supported by research grants from the Flemish
League against Cancer and Varian.
REFERENCES
1. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J,
et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. (2017) 28(suppl_4):iv1–21. doi: 10.1093/annonc/mdx222
2. Abuodeh Y, Venkat P, Kim S. Systematic review of case reports
on the abscopal effect. Curr Probl Cancer. (2016) 40:25–37.
doi: 10.1016/j.currproblcancer.2015.10.001
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting:
from immunosurveillance to tumor escape. Nat Immunol. (2002) 3:991–8.
doi: 10.1038/ni1102-991
4. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity
cycle. Immunity. (2013) 39:1–10. doi: 10.1016/j.immuni.2013.07.012
5. Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. The
convergence of radiation and immunogenic cell death signaling pathways.
Front Oncol. (2012) 2:88. doi: 10.3389/fonc.2012.00088
6. Durante M, Formenti SC. Radiation-induced chromosomal aberrations and
immunotherapy: micronuclei, cytosolic DNA, and interferon-production
pathway. Front Oncol. (2018) 8:192. doi: 10.3389/fonc.2018.00192
7. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-
Dependent cytosolic DNA sensing promotes radiation-induced
type I interferon-dependent antitumor immunity in immunogenic
tumors. Immunity. (2014) 41:843–52. doi: 10.1016/j.immuni.2014.
10.019
8. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM,
Schneider RJ. et al. DNA exonuclease Trex1 regulates radiotherapy-
induced tumour immunogenicity. Nat Commun. (2017) 8:15618.
doi: 10.1038/ncomms15618
9. Hellevik T, Martinez-Zubiaurre I. Radiotherapy and the tumor stroma:
the importance of dose and fractionation. Front Oncol. (2014) 4:1.
doi: 10.3389/fonc.2014.00001
10. Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita
H. et al. Radiotherapy promotes tumor-specific effector CD8+ T
cells via dendritic cell activation. J Immunol. (2012) 189:558–66.
doi: 10.4049/jimmunol.1200563
11. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al.
Therapeutic effects of ablative radiation on local tumor require CD8+ T
cells: changing strategies for cancer treatment. Blood. (2009) 114:589–95.
doi: 10.1182/blood-2009-02-206870
Frontiers in Medicine | www.frontiersin.org 13 November 2019 | Volume 6 | Article 244
Spaas and Lievens Immuno-Radiotherapy in NSCLC
12. Martinez-Zubiaurre I, Chalmers AJ, Hellevik T. Radiation-induced
transformation of immunoregulatory networks in the tumor stroma. Front
Immunol. (2018) 9:1679. doi: 10.3389/fimmu.2018.01679
13. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M,
Cameron TO, et al. Radiation-induced CXCL16 release by breast
cancer cells attracts effector T cells. J Immunol. (2008) 181:3099–107.
doi: 10.4049/jimmunol.181.5.3099
14. Kim JY, Son YO, Park SW, Bae JH, Chung JS, Kim HH, et al. Increase of
NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor
cells by heat shock and ionizing radiation. Exp Mol Med. (2006) 38:474–84.
doi: 10.1038/emm.2006.56
15. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN,
et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic
activity and CTL adoptive immunotherapy. J Immunol. (2003) 170:6338–47.
doi: 10.4049/jimmunol.170.12.6338
16. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley
EK, et al. Radiation modulates the peptide repertoire, enhances MHC class
I expression, and induces successful antitumor immunotherapy. J Exp Med.
(2006) 203:1259–71. doi: 10.1084/jem.20052494
17. Vatner RE, Formenti SC. Myeloid-derived cells in tumors:
effects of radiation. Semin Radiat Oncol. (2015) 25:18–27.
doi: 10.1016/j.semradonc.2014.07.008
18. Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou
JS, et al. Radiation enhances regulatory T cell representation. Int J Radiat
Oncol Biol Phys. (2011) 81:1128–35. doi: 10.1016/j.ijrobp.2010.09.034
19. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, et al.
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-
induced acceleration of metastatic cancer progression. J Clin Invest. (2017)
127:1116. doi: 10.1172/JCI93333
20. Ostrand-Rosenberg S, Horn LA, Ciavattone NG. Radiotherapy both
promotes and inhibits myeloid-derived suppressor cell function: novel
strategies for preventing the tumor-protective effects of radiotherapy. Front
Oncol. (2019) 9:215. doi: 10.3389/fonc.2019.00215
21. Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, et al.
T-cell responses to survivin in cancer patients undergoing radiation therapy.
Clin Cancer Res. (2008) 14:4883–90. doi: 10.1158/1078-0432.CCR-07-4462
22. Tabi Z, Spary LK, Coleman S, Clayton A, Mason MD, Staffurth J. Resistance
of CD45RA- T cells to apoptosis and functional impairment, and activation
of tumor-antigen specific T cells during radiation therapy of prostate cancer.
J Immunol. (2010) 185:1330–9. doi: 10.4049/jimmunol.1000488
23. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW.
Sublethal irradiation of human tumor cells modulates phenotype resulting in
enhanced killing by cytotoxic T lymphocytes. Cancer Res. (2004) 64:7985–94.
doi: 10.1158/0008-5472.CAN-04-1525
24. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor
immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. (2012)
83:1306–10. doi: 10.1016/j.ijrobp.2011.09.049
25. Dorta-Estremera S, Colbert LE, Nookala SS, Yanamandra AV, Yang G,
Delgado A, et al. Kinetics of intratumoral immune cell activation during
chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys. (2018)
102:593–600. doi: 10.1016/j.ijrobp.2018.06.404
26. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-
dose irradiation programs macrophage differentiation to an iNOS(+)/M1
phenotype that orchestrates effective T cell immunotherapy. Cancer Cell.
(2013) 24:589–602. doi: 10.1016/j.ccr.2013.09.014
27. Meng Y, Yu Z, Wu Y, Du T, Chen S, Meng F, et al. Cell-based
immunotherapy with cytokine-induced killer (CIK) cells: From preparation
and testing to clinical application. Hum Vaccin Immunother. (2017) 13:1–9.
doi: 10.1080/21645515.2017.1285987
28. DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J,
Rajasekhar VK, et al. Low-dose radiation conditioning enables CAR
T cells to mitigate antigen escape. Mol Ther. (2018) 26:2542–52.
doi: 10.1016/j.ymthe.2018.09.008
29. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and
immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. (2017) 14:365–79.
doi: 10.1038/nrclinonc.2016.211
30. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum
RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote
antitumor immunity in mice. J Clin Invest. (2014) 124:687–95. doi: 10.1172/
JCI67313
31. Antonia SJ, Villegas A, Daniel D, Vicente D,Murakami S, Hui R, et al. Overall
survival with durvalumab after chemoradiotherapy in stage III NSCLC. N
Engl J Med. (2018) 379:2342–50. doi: 10.1056/NEJMoa1809697
32. Faivre-Finn C, Spigel DR, Senan S, Langer CJ, Raben D, Perz, B, et al. Efficacy
and safety evaluation based on time from completion of radiotherapy to
randomization with durvalumab or placebo in pts from PACIFIC. Ann
Oncol. (2018) 29(suppl_8):mdy291. doi: 10.1093/annonc/mdy291
33. Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review
of the influence of radiation-induced lymphopenia on survival
outcomes in solid tumors. Crit Rev Oncol Hematol. (2018) 123:42–51.
doi: 10.1016/j.critrevonc.2018.01.003
34. Grassberger C, Ellsworth SG,Wilks MQ, Keane FK, Loeffler JS. Assessing the
interactions between radiotherapy and antitumour immunity. Nat Rev Clin
Oncol. (2019). doi: 10.1038/s41571-019-0238-9. [Epub ahead of print].
35. Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, et al.
Lymphopenia association with gross tumor volume and lung V5 and its
effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol
Biol Phys. (2014) 89:1084–91. doi: 10.1016/j.ijrobp.2014.04.025
36. Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The
etiology of treatment-related lymphopenia in patients with malignant
gliomas: modeling radiation dose to circulating lymphocytes explains
clinical observations and suggests methods of modifying the impact
of radiation on immune cells. Cancer Invest. (2013) 31:140–4.
doi: 10.3109/07357907.2012.762780
37. Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact
of radiation dose to the host immune system on tumor control and
survival for stage III non-small cell lung cancer treated with definitive
radiation therapy. Int J Radiat Oncol Biol Phys. (2019) 105:346–55.
doi: 10.1016/j.ijrobp.2019.05.064
38. Sellins KS, Cohen JJ. Gene induction by gamma-irradiation leads to DNA
fragmentation in lymphocytes. J Immunol. (1987) 139:3199–206.
39. Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM,
Francica BJ, et al. Elective nodal irradiation attenuates the combinatorial
efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer
Res. (2018) 24:5058–71. doi: 10.1158/1078-0432.CCR-17-3427
40. Price JG, Idoyaga J, Salmon H, Hogstad B, Bigarella CL, Ghaffari S,
et al. CDKN1A regulates Langerhans cell survival and promotes Treg cell
generation upon exposure to ionizing irradiation. Nat Immunol. (2015)
16:1060–8. doi: 10.1038/ni.3270
41. Wirsdörfer F, de Leve S, Jendrossek V. Combining radiotherapy
and immunotherapy in lung cancer: can we expect limitations
due to altered normal tissue toxicity? Int J Mol Sci. (2018) 20:E24.
doi: 10.3390/ijms20010024
42. Louvel G, Bahleda R, Ammari S, Le Péchoux C, Levy A, Massard C,
et al. Immunotherapy and pulmonary toxicities: can concomitant
immune-checkpoint inhibitors with radiotherapy increase the
risk of radiation pneumonitis? Eur Respir J. (2018) 51:1701737.
doi: 10.1183/13993003.01737-2017
43. Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA,
et al. Pneumonitis in non-small cell lung cancer patients receiving immune
checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol.
(2018) 13:1930–9. doi: 10.1016/j.jtho.2018.08.2035
44. Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence,
treatment, and survival of patients with lung cancer in the last four decades.
Cancer Manag Res. (2019) 11:943–53. doi: 10.2147/CMAR.S187317
45. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al.
Standard-dose versus high-dose conformal radiotherapy with concurrent
and consolidation carboplatin plus paclitaxel with or without cetuximab for
patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617):
a randomised, two-by-two factorial phase 3 study. Lancet Oncol. (2015)
16:187–99. doi: 10.1016/S1470-2045(14)71207-0
46. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B,
et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or
etoposide-cisplatin plus thoracic radiation therapy followed by consolidation
chemotherapy in locally advanced nonsquamous non-small-cell lung cancer.
J Clin Oncol. (2016) 34:953–62. doi: 10.1200/JCO.2015.64.8824
Frontiers in Medicine | www.frontiersin.org 14 November 2019 | Volume 6 | Article 244
Spaas and Lievens Immuno-Radiotherapy in NSCLC
47. Garg S, Gielda BT, Kiel K, Turian JV, Fidler MJ, Batus M, et al. Patterns
of locoregional failure in stage III non-small cell lung cancer treated with
definitive chemoradiation therapy. Pract Radiat Oncol. (2014) 4:342–8.
doi: 10.1016/j.prro.2013.12.002
48. Ohyanagi F, Horai T, Sekine I, Yamamoto N, Nakagawa K, Nishio M, et al.
Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with
unresectable stage III NSCLC after primary chemoradiotherapy: preliminary
results from a Phase I/II study. Jpn J Clin Oncol. (2011) 41:718–22.
doi: 10.1093/jjco/hyr021
49. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D,
et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage
IIIB and IV non-small-cell lung cancer. J Clin Oncol. (2005) 23:6674–81.
doi: 10.1200/JCO.2005.13.011
50. Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K,
Szczesna A, et al. Tecemotide in unresectable stage III non-small-cell lung
cancer in the phase III START study: updated overall survival and biomarker
analyses. Ann Oncol. (2015) 26:1134–42. doi: 10.1093/annonc/mdv104
51. Patel J, Lee J, Wagner H Jr, Carbone D, Shanker A, Horn L, et al.
Phase II study of immunotherapy with tecemotide and bevacizumab after
chemoradiation in unresectable stage III NS-NSCLC. J Thorac Oncol. (2018)
13:S370. doi: 10.1016/j.jtho.2018.08.349
52. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas
M, et al. Telomerase peptide vaccination in NSCLC: a phase II trial
in stage III patients vaccinated after chemoradiotherapy and an 8-
year update on a phase I/II trial. Clin Cancer Res. (2011) 17:6847–57.
doi: 10.1158/1078-0432.CCR-11-1385
53. Pujol JL, Vansteenkiste JF, De Pas TM, Atanackovic D, Reck M, Thomeer M,
et al. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic
with or without Adjuvant Chemotherapy in Patients with Resected Stage
IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. J Thorac Oncol.
(2015) 10:1458–67. doi: 10.1097/JTO.0000000000000653
54. Durm G, Althouse S, Sadiq A, Jalal S, Jabbour S, Zon R, et al. Updated
results of a phase II trial of concurrent chemoradiation with consolidation
pembrolizumab in patients with unresectable stage III NSCLC. J Thorac
Oncol. (2018) 13:S321. doi: 10.1016/j.jtho.2018.08.238
55. Lin S, Lin X, Clay D, Yao L, Mok I, Gomez D, et al. DETERRED: phase
II trial combining atezolizumab concurrently with chemoradiation therapy
in locally advanced non-small cell lung cancer. J Thorac Oncol. (2018)
13:S320–1. doi: 10.1016/j.jtho.2018.08.237
56. Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, et al.
Safety evaluation of nivolumab added concurrently to radiotherapy in a
standard first line chemo-radiotherapy regimen in stage III non-small cell
lung cancer-The ETOP NICOLAS trial. Lung Cancer. (2019) 133:83–7.
doi: 10.1016/j.lungcan.2019.05.001
57. Peters S, FeliP E, Dafni U, Tufman A, Guckenberger M, Irigoyen A,
et al. Efficacy evaluation of concurrent nivolumab addition to a first-line,
concurrent chemo-radiotherapy regimen in unresectable locally advanced
NSCLC: results from the European Thoracic Oncology Platform (ETOP
6–14) NICOLAS phase II trial. Ann Oncol. (2019) 30(Suppl. 5):mdz259.
doi: 10.1093/annonc/mdz259
58. Alexandroff AB, Jackson AM, O’Donnell MA, James K. BCG
immunotherapy of bladder cancer: 20 years on. Lancet. (1999) 353:1689–94.
doi: 10.1016/S0140-6736(98)07422-4
59. Pines A. A 5-year controlled study of B.C.G. and radiotherapy inoperable
lung cancer. Lancet. (1976) 1:380–1. doi: 10.1016/S0140-6736(76)90213-0
60. Robinson E, Bartal A, Cohen Y, Haasz R, Mekori T. Treatment of
lung cancer by radiotherapy, chemotherapy, and methanol extraction
residue of BCG (MER): clinical and immunological studies. Cancer.
(1977) 40:1052–9. doi: 10.1002/1097-0142(197709)40:3&lt;1052::AID-
CNCR2820400313&gt;3.0.CO;2-G
61. Robinson E, Haim N, Segal R, Veseley Z, Mekori T. Combined-modality
treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy,
and radiotherapy). Cancer Treat Rep. (1985) 69:251–8.
62. Ruckdeschel JC, de Leve S, Jendrossek V. Regional immunotherapy
has a detrimental effect on the response to combined irradiation and
chemotherapy in locally advanced non-small cell bronchogenic carcinoma.
Cancer Immunol Immunother. (1981) 11:277–82. doi: 10.1007/BF00198972
63. White JE, Chen T, Reed R, Mira J, Stuckey WJ, Weatherall T, et al.
Limited squamous cell carcinoma of the lung: a Southwest Oncology Group
randomized study of radiation with or without doxorubicin chemotherapy
and with or without levamisole immunotherapy. Cancer Treat Rep.
(1982) 66:1113–20.
64. Perez CA, Bauer M, Emami BN, Byhardt R, Brady LW, Doggett RL,
et al. Thoracic irradiation with or without levamisole (NSC #177023) in
unresectable non-small cell carcinoma of the lung: a phase III randomized
trial of the RTOG. Int J Radiat Oncol Biol Phys. (1988) 15:1337–46.
doi: 10.1016/0360-3016(88)90229-5
65. Herskovic A, Bauer M, Seydel HG, Yesner R, Doggett RL, Perez CA,
et al. Post-operative thoracic irradiation with or without levamisole
in non-small cell lung cancer: results of a Radiation Therapy
Oncology Group Study. Int J Radiat Oncol Biol Phys. (1988) 14:37–42.
doi: 10.1016/0360-3016(88)90048-X
66. Van Houtte P, Bondue H, Rocmans P, Michel J, Wybran J, Dalesio
O, et al. Adjuvant immunotherapy by levamisole in resectable
lung cancer: a control study. Eur J Cancer. (1980) 16:1597–601.
doi: 10.1016/0014-2964(80)90033-X
67. Krauss S, Comas F, Perez C, Gordon D, Philpott G, Broun G, et al.
Treatment of inoperable non-small cell carcinoma of the lung with
radiation therapy, with or without levamisole. A randomized trial of the
Southeastern Cancer Study group. Am J Clin Oncol. (1984) 7:405–12.
doi: 10.1097/00000421-198410000-00003
68. Ogawa Y, Kimura S, Imajo Y, Hamada F, Miyaji C, Imanaka K, et al.
[Evaluation of concomitant use of non-specific immunopotentiator on 172
cases of primary lung cancer (stage III, IV) treated with radiation combined
with chemotherapy (author’s transl)]. Rinsho Hoshasen. (1982) 27:451–4.
69. Maasilta P, Holsti LR, Halme M, Kivisaari L, Cantell K, Mattson K. Natural
alpha-interferon in combination with hyperfractionated radiotherapy in the
treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. (1992)
23:863–8. doi: 10.1016/0360-3016(92)90660-A
70. Shaw EG, Deming RL, Creagan ET, Nair S, Su JQ, Levitt R, et al. Pilot study
of human recombinant interferon gamma and accelerated hyperfractionated
thoracic radiation therapy in patients with unresectable stage IIIA/B
nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. (1995) 31:827–31.
doi: 10.1016/0360-3016(94)00462-5
71. Bradley JD, Scott CB, Paris KJ, Demas WF, Machtay M, Komaki R, et al.
A phase III comparison of radiation therapy with or without recombinant
beta-interferon for poor-risk patients with locally advanced non-small-cell
lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys. (2002) 52:1173–9.
doi: 10.1016/S0360-3016(01)02797-3
72. Franco-Molina MA, Mendoza-Gamboa E, Zapata-Benavides P, Vera-García
ME, Castillo-Tello P, García de la Fuente A, et al. IMMUNEPOTENT CRP
(bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I
study in non-small cell lung cancer patients. Cytotherapy. (2008) 10:490–6.
doi: 10.1080/14653240802165681
73. Butts C, Socinski MA,Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III
non-small-cell lung cancer (START): a randomised, double-blind, phase 3
trial. Lancet Oncol. (2014) 15:59–68. doi: 10.1016/S1470-2045(13)70510-2
74. Chen W, Shin KH, Kim S, Shon WJ, Kim RH, Park NH, et al. hTERT
peptide fragment GV1001 demonstrates radioprotective and antifibrotic
effects through suppression of TGFbeta signaling. Int J Mol Med. (2018)
41:3211–20. doi: 10.3892/ijmm.2018.3566
75. Qian H, Wang H, Guan X, Yi Z, Ma F. Adoptive immunotherapy combined
chemoradiotherapy for non-small-cell lung cancer: a meta-analysis.
Anticancer Drugs. (2016) 27:433–8. doi: 10.1097/CAD.0000000000000346
76. Xiao Z, Wang CQ, Zhou MH, Li NN, Liu SY, He YJ, et al. Clinical efficacy
and safety of CIK plus radiotherapy for lung cancer: a meta-analysis of
16 randomized controlled trials. Int Immunopharmacol. (2018) 61:363–75.
doi: 10.1016/j.intimp.2018.06.012
77. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al.
Durvalumab after chemoradiotherapy in stage III non-small-cell lung
cancer. N Engl J Med. (2017) 377:1919–29. doi: 10.1056/NEJMoa1709937
78. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al.
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines
Frontiers in Medicine | www.frontiersin.org 15 November 2019 | Volume 6 | Article 244
Spaas and Lievens Immuno-Radiotherapy in NSCLC
for diagnosis, treatment and follow-up. Ann Oncol. (2019) 30:863–70.
doi: 10.1093/annonc/mdy474
79. Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B,
Faivre-Finn C, et al. Definition of synchronous oligo-metastatic
non-small cell lung cancer - a consensus report. J Thorac Oncol. (2019).
doi: 10.1016/j.jtho.2019.07.025. [Epub ahead of print].
80. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares
M, Camidge DR. Is there a role for consolidative stereotactic body
radiation therapy following first-line systemic therapy for metastatic lung
cancer? A patterns-of-failure analysis. Acta Oncol. (2009) 48:578–83.
doi: 10.1080/02841860802662722
81. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ,
et al. Local consolidative therapy vs. maintenance therapy or observation for
patients with oligometastatic non-small-cell lung cancer: long-term results
of a multi-institutional, phase ii, randomized study. J Clin Oncol. (2019)
37:1558–65. doi: 10.1200/JCO.19.00201
82. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al.
Consolidative radiotherapy for limited metastatic non-small-cell lung
cancer: a phase 2 randomized clinical trial. JAMA Oncol. (2018) 4:e173501.
doi: 10.1001/jamaoncol.2017.3501
83. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C,
et al. Stereotactic ablative radiotherapy versus standard of care palliative
treatment in patients with oligometastatic cancers (SABR-COMET):
a randomised, phase 2, open-label trial. Lancet. (2019) 393:2051–8.
doi: 10.1016/S0140-6736(18)32487-5
84. van den Heuvel MM, Verheij M, Boshuizen R, Belderbos J, Dingemans AM,
De Ruysscher D, et al. NHS-IL2 combined with radiotherapy: preclinical
rationale and phase Ib trial results in metastatic non-small cell lung
cancer following first-line chemotherapy. J Transl Med. (2015) 13:32.
doi: 10.1186/s12967-015-0397-0
85. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-
Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-
stimulating factor to generate abscopal responses in patients with metastatic
solid tumours: a proof-of-principle trial. Lancet Oncol. (2015) 16:795–803.
doi: 10.1016/S1470-2045(15)00054-6
86. Ohri N, Halmos B, Cheng H, Abrahmam T, Yahya T, Garg M, et al.
FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced
non-small cell lung cancer. Cancer Res. (2018) 78(13 Suppl.):CT005.
doi: 10.1158/1538-7445.AM2018-CT005
87. Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C,
et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-
based active cancer immunotherapy, BI1361849 (CV9202), combined with
local radiation treatment in patients with stage IV non-small cell lung cancer.
J Immunother Cancer. (2019) 7:38. doi: 10.1186/s40425-019-0520-5
88. Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C,
et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Nat Med. (2018) 24:1845–51. doi: 10.1038/s41591-018-0232-2
89. Tang C, de Groot P, Hess K, Shabaan S, Gomez DR, Chang JY, et al. Phase
1 study of pembrolizumab and stereotactic or hypofractionated radiation for
metastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. (2017)
99:S160–1. doi: 10.1016/j.ijrobp.2017.06.370
90. Kumar R, Walder DP, Pejanaute A, Gunapala R, Bhosle J, Yousef N, et al.
Phase I dose escalation of pembrolizumab given concurrently with palliative
thoracic radiotherapy (RT) for NSCLC. Ann Oncol. (2018) 29(Suppl.
8):mdy292.087. doi: 10.1093/annonc/mdy292.087
91. Decker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, et al. A
phase i/ii trial evaluating the combination of stereotactic body radiotherapy
and pembrolizumab in metastatic NSCLC: topic: IT. J Thorac Oncol. (2017)
12:S1303–4. doi: 10.1016/j.jtho.2016.11.1843
92. Moreno V, Gil-Martin M, Johnson M, Aljumaily R, Lopez-Crido MP,
Northfelt D, et al. Cemiplimab, a human monoclonal anti-PD-1, alone or in
combination with radiotherapy: phase 1 NSCLC expansion cohorts. J Thorac
Oncol. (2018) 13:S366. doi: 10.1016/j.jtho.2018.08.340
93. Alameddine R, Wong P, Masucci L, Roberge D, Menard C, Routy
B, et al. Early safety data of a phase I/II combining nivolumab and
stereotactic brain radiosurgery for treatment of brain metastases in patients
with NSCLC. J Thorac Oncol. (2018) 13:S385. doi: 10.1016/j.jtho.2018.
08.384
94. Miyamoto S, Nomura R, Sato K, Awano N, Kuse N, Inomata M, et al.
Nivolumab and stereotactic radiation therapy for the treatment of patients
with Stage IV non-small-cell lung cancer. Jpn J Clin Oncol. (2019) 49:160–4.
doi: 10.1093/jjco/hyy171
95. Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries
JF, Aerts JGJV, et al. Effect of pembrolizumab after stereotactic body
radiotherapy vs pembrolizumab alone on tumor response in patients
with advanced non-small cell lung cancer: results of the PEMBRO-
RT Phase 2 randomized clinical trial. JAMA Oncol. (2019) 5:1276–82.
doi: 10.1001/jamaoncol.2019.1478
96. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, et al.
Safety and clinical activity of pembrolizumab and multisite stereotactic body
radiotherapy in patients with advanced solid tumors. J Clin Oncol. (2018)
36:1611–8. doi: 10.1200/JCO.2017.76.2229
97. Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T,
et al. Pembrolizumab after completion of locally ablative therapy for
oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol.
(2019) 5:1283–90. doi: 10.1001/jamaoncol.2019.1449
98. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, et al.
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine,
as maintenance therapy for non-small cell lung cancer. Eur J Cancer. (2015)
51:2321–9. doi: 10.1016/j.ejca.2015.07.035
99. Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, et al.
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201
in patients with stage IIIB/IV non-small cell lung cancer. Cancer Immunol
Immunother. (2019) 68:799–812. doi: 10.1007/s00262-019-02315-x
100. Campbell AM, CaiWL, Burkhadt D, Gettinger SN, Goldberg SB, AmodioM,
et al. Final results of a phase ii prospective trial evaluating the combination
of stereotactic body radiotherapy (sbrt) with concurrent pembrolizumab in
patients with metastatic non-small cell lung cancer (NSCLC). Int J Radiat
Oncol Biol Phys. (2019) 105:S36–7. doi: 10.1016/j.ijrobp.2019.06.453
101. Brooks ED, Chang JY. Time to abandon single-site irradiation for
inducing abscopal effects. Nat Rev Clin Oncol. (2019) 16:123–35.
doi: 10.1038/s41571-018-0119-7
102. van den Berg LL, Klinkenberg TJ, Groen HJ, Widder J. Patterns of recurrence
and survival after surgery or stereotactic radiotherapy for early stage NSCLC.
J Thorac Oncol. (2015) 10:826–31. doi: 10.1097/JTO.0000000000000483
103. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the
patterns of failure following stereotactic body radiation therapy in early-stage
non-small-cell lung cancer: clinical implications. Radiother Oncol. (2010)
94:1–11. doi: 10.1016/j.radonc.2009.12.008
104. Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of
disease recurrence after stereotactic ablative radiotherapy for early stage
non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. (2012)
13:802–9. doi: 10.1016/S1470-2045(12)70242-5
105. Matsuo Y, Shibuya K, Nagata Y, Takayama K, Norihisa Y, Mizowaki
T, et al. Prognostic factors in stereotactic body radiotherapy for non-
small-cell lung cancer. Int J Radiat Oncol Biol Phys. (2011) 79:1104–11.
doi: 10.1016/j.ijrobp.2009.12.022
106. Leeman JE, Rimner A, Montecalvo J, Hsu M, Zhang Z, von Reibnitz D, et al.
Histologic subtype in core lung biopsies of early-stage lung adenocarcinoma
is a prognostic factor for treatment response and failure patterns after
stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. (2017)
97:138–45. doi: 10.1016/j.ijrobp.2016.09.037
107. Zhang T, Yu H, Ni C, Zhang T, Liu L, Lv Q, et al. Hypofractionated
stereotactic radiation therapy activates the peripheral immune response
in operable stage I non-small-cell lung cancer. Sci Rep. (2017) 7:4866.
doi: 10.1038/s41598-017-04978-x
Conflict of Interest: YL reports expert positions for AstraZeneca and RaySearch,
outside the current work.
The remaining author declares that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2019 Spaas and Lievens. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Medicine | www.frontiersin.org 16 November 2019 | Volume 6 | Article 244
